肿瘤细胞治疗研究
英文原题：Targeting CD22 for B-cell hematologic malignancies.
然而，30%-60% 的患者最终复发，其中 CD19 阴性复发是持续缓解的重要障碍。
靶向CD19的嵌合抗原受体（CAR）T细胞疗法治疗复发或难治性（R/R）B细胞恶性肿瘤已显示显著临床疗效。然而，30%至60%的患者最终复发，其中CD19阴性复发是维持缓解的重要障碍。恶性B细胞中的CD22表达不依赖于CD19，因此CD22是治疗CD19 CAR-T耐药患者的潜在替代靶点。以抗体药物偶联物（ADC）和CAR-T细胞为主的CD22靶向疗法已广泛进入临床应用，并显示可接受的毒性和良好疗效。本综述探讨CD22的分子和生理特征、CD22 ADC和CAR-T细胞的开发，以及现有临床数据，并提出克服肿瘤逃逸、提高CD22靶向治疗疗效的思路。
CD19-targeted chimeric receptor antigen (CAR)-T cell therapy has shown remarkable clinical efficacy in the treatment of relapsed or refractory (R/R) B-cell malignancies. However, 30%-60% of patients eventually relapsed, with the CD19-negative relapse being an important hurdle to sustained remission. CD22 expression is independent of CD19 expression in malignant B cells. Consequently, CD22 is a potential alternative target for CD19 CAR-T cell-resistant patients. CD22-targeted therapies, mainly including the antibody-drug conjugates (ADCs) and CAR-T cells, have come into wide clinical use with acceptable toxicities and promising efficacy. In this review, we explore the molecular and physiological characteristics of CD22, development of CD22 ADCs and CAR-T cells, and the available clinical data on CD22 ADCs and CAR-T cell therapies. Furthermore, we propose some perspectives for overcoming tumor escape and enhancing the efficacy of CD22-targeted therapies.
MEMBER ACCOUNT
登录成功会直接打开下一页。
